R H J Mathijssen
Overview
Explore the profile of R H J Mathijssen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
960
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buijs S, Mohmaed Ali M, Oomen-de Hoop E, Braal C, Wortelboer N, van Ommen-Nijhof A, et al.
ESMO Open
. 2025 Feb;
10(3):104290.
PMID: 39954390
Background: Data on exposure-response or exposure-toxicity relationships of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are limited and inconclusive. We aimed to investigate whether there is an association between palbociclib exposure and...
2.
Agema B, Berrich M, Seuren L, Sassen S, Miedema J, Koch B, et al.
Biomed Pharmacother
. 2024 Aug;
179:117341.
PMID: 39191023
Background: Nintedanib is used to treat both idiopathic and progressive pulmonary fibrosis (IPF/PPF). Evidence of both an exposure-response relationship and an exposure-toxicity relationship has been found, suggesting the potential value...
3.
Giraud E, Westerdijk K, van der Kleij M, Guchelaar N, Meertens M, Bleckman R, et al.
ESMO Open
. 2024 Jun;
9(6):103477.
PMID: 38833964
Background: Sunitinib is an oral anticancer drug approved for the treatment of among others gastrointestinal stromal tumor (GIST). Previous analyses demonstrated an exposure-response relationship at the standard dose, and minimum...
4.
Heine R, Thielen F, Mathijssen R, van Leeuwen R, Franken M, Uyl-de Groot C
PLoS One
. 2024 Feb;
19(2):e0293264.
PMID: 38300937
Background: Expanding the indication of already approved immuno-oncology drugs presents treatment opportunities for patients but also strains healthcare systems. Cost-based pricing models are discussed as a possibility for cost containment....
5.
de Joode K, van de Geer W, van Leenders G, Hamberg P, Westgeest H, Beeker A, et al.
Sci Rep
. 2023 Jul;
13(1):10720.
PMID: 37400554
Differences in the clinical course and treatment responses in individual patients with advanced renal cell carcinoma (RCC) can largely be explained by the different genomics of this disease. To improve...
6.
de With M, Sadlon A, Cecchin E, Haufroid V, Thomas F, Joerger M, et al.
ESMO Open
. 2023 Mar;
8(2):101197.
PMID: 36989883
Background: The main cause for fluoropyrimidine-related toxicity is deficiency of the metabolizing enzyme dihydropyrimidine dehydrogenase (DPD). In 2020, the European Medicines Agency (EMA) recommended two methods for pre-treatment DPD deficiency...
7.
Buijs S, Oomen-de Hoop E, Braal C, van Rosmalen M, Drooger J, van Rossum-Schornagel Q, et al.
ESMO Open
. 2023 Feb;
8(1):100786.
PMID: 36753991
Background: Tamoxifen is important in the adjuvant treatment of hormone-sensitive breast cancer and substantially reduces recurrence; however, almost 50% of patients are non-compliant mainly due to side-effects. The aim of...
8.
IJzerman N, van Werkhoven E, Mohammadi M, Hollander D, Bleckman R, Reyners A, et al.
ESMO Open
. 2022 Dec;
7(6):100649.
PMID: 36493601
Background: Sex differences in cancer have gained attention in recent years. The role of sex as a prognostic factor in gastrointestinal stromal tumours (GIST) has not been well established. The...
9.
Groenland S, van Eerden R, Westerdijk K, Meertens M, Koolen S, Moes D, et al.
Ann Oncol
. 2022 Jul;
33(10):1071-1082.
PMID: 35777707
Background: Oral targeted therapies show a high pharmacokinetic (PK) interpatient variability. Even though exposure has been positively correlated with efficacy for many of these drugs, these are still dosed using...
10.
de Joode K, Oostvogels A, GeurtsvanKessel C, de Vries R, Mathijssen R, Debets R, et al.
Front Immunol
. 2021 Feb;
12:627186.
PMID: 33613575
After the COVID-19 outbreak, non-evidence based guidelines were published to advise clinicians on the adjustment of oncological treatment during this pandemic. As immune checkpoint inhibitors directly affect the immune system,...